Expression of LC3-I, LC3-II & Beclin 1 in Vitiligo

Cairo University (CU)

Status: Unknown

Conditions: Autophagy

Treatments: Other: skin biopsy

Study type: Interventional

Funder types: Other

Identifiers

NCT03371758

Dermatology

Details and patient eligibility

About

The exact mechanism of impairment of autophagy in vitiligo has not yet been determined.

Enrollment: 40 estimated patients

Sex: All

Ages: 12+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• • Patients with non-segmental vitiligo whether active or stable.

  • Age above 12 years.
  • Both sexes.

Exclusion criteria

• • Patients should not use any topical or systemic treatment at least 6 weeks before inclusion into the study.

  • Patients having other autoimmune disease, heart disease, liver disease, kidney disease, neurological disorder, cancer, active infection or any chronic disease.
  • Pregnancy or breast feeding for female patients.

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

40 participants in 2 patient groups

vitiligo patients

Experimental group

Treatment:

Other: skin biopsy

healthy controls

Experimental group

Treatment:

Other: skin biopsy